Aehr Test Systems has clawed back 7.6% on the week to $72.01, but the recovery masks a stubborn short base and a C-suite that is visibly trimming into strength — a combination that makes the bounce harder to read than the headline number suggests.
The short position has not softened despite the post-earnings rally. At 14.2% of free float — roughly 4.25 million shares — short interest is up 3% on the week, meaning bears added exposure into the rebound rather than covering it. That said, the borrow market offers little ammunition to squeeze them: availability is wide open at nearly 800%, with more than seven shares available to lend for every one currently borrowed. Cost to borrow has edged up 14% on the week but remains negligible at 0.45%. Shorts are holding patient, well-funded positions — not a crowded trade under pressure. Options are shifting the other way. The put/call ratio has dropped to 0.81, almost two standard deviations below its 20-day average of 0.89, the lowest defensive reading since June 1. That signals options traders are rotating toward calls and expressing more bullish conviction than at any point in the past six weeks — a notable divergence from where short sellers are positioned.
The Street is harder to read clearly. The most recent analyst actions on record are from early March — William Blair upgraded to Outperform and Freedom Broker lifted its target to $38 — but both are now more than four months stale and predate the stock's current $72 level. The mean price target of $108 looks directionally consistent with the current price, but given the age and limited coverage, that figure should be treated as indicative rather than precise. What is clearer is the valuation picture: the stock carries a P/E above 500 and an EV/EBITDA north of 250, pricing in substantial recovery in earnings that has yet to materialise. The factor score on short interest ranks in just the 15th percentile — meaning most comparable names carry less short exposure — while EPS momentum over 90 days sits at zero, the weakest end of the range.
The most concrete development of the week remains the insider cluster, which was detailed in the note published earlier today. The update here is that selling continued on July 14, with the EVP adding to the prior session's exits. The 90-day net insider position is still a modest positive at roughly 50,000 shares, so the aggregate picture is trimming rather than abandonment. But five named officers selling across two consecutive sessions — CEO, CFO, COO, CTO and EVP — all at significance scores of 1, consistent with pre-arranged plans, remains the most visible signal the data offers. Peer context sharpens the comparison: CAMT gained 12.5% on the week and FORM added nearly 10%, while SMTC rose 11.8%. AEHR's 7.6% gain is a recovery, but it trails the cohort that was selling off harder into earnings.
The next scheduled earnings event is October 5 — roughly 12 weeks out. Between now and then, the tension worth watching is whether the post-earnings rally can sustain against a short base that has refused to retreat, insider selling that has continued on both sides of the print, and a valuation that demands the earnings recovery arrives on schedule.
See the live data behind this article on ORTEX.
Open AEHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
